CNCR
Range Cancer Therapeutics ETF
This fund tracks the Loncar Cancer Immunotherapy Index, an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.
US
EQUITY
Passive
MANAGEMENT STYLE
$ 7.0 M
ASSETS UNDER MGMT
79 bp
EXPENSES
Fund Basics
| Inception date | Oct 13, 2015 |
| Regulation | Open-End Investment Company |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| CASH & OTHER | 100.0 % |
Constituent Breakdown
| Number of holdings | 63 |
| Herfindahl-Hirschman Index | 10,002 |
| Wgt avg mkt cap (mns) | $0 |
| Large cap (>$10bn) | 0.0% |
| Mid cap ($2-10bn) | 0.0% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 0.0% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
Historical Performance
Standardized Performance (as of 10/31/2025)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -26.7% | -41.0% | -16.5% | -17.4% | -18.6% | -- | -- | -9.9% |
| Dividend Yield | 26.7% | 41.0% | 16.5% | 17.4% | 18.6% | -- | -- | 9.9% |
| Total Returns | -- | -- | -- | -- | -- | -- | -- | -- | Ann. Volatility | 45.2% | 40.2% | 37.1% | 35.3% | 35.1% | -- | -- | 34.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.50 | 30% |
| MSCI EAFE | 1.75 | 15% |
| MSCI Emg Mkts | 1.03 | 9% |
Liquidity Measures
| Avg. volume (000) | 0 |
| ADV traded (mns) | $0 |
| Turnover | 0.0% |
| Avg. Bid/Ask (% of price) | 1.00% |
Technical Indicators
| 30d moving avg. (EMA) | $9.24 |
| Relative strength (RSI) | 44 |
| MACD/Signal | -0.19/-0.20 |
| Bollinger Bands (Upper/Lower) | $10.10/$8.26 |
| Short interest (% of AUM) | 0.9% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. CNCR |
Expenses vs. CNCR |
ALTAR Score™ vs. CNCR |
|---|
Risk and Returns: CNCR vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | ||||
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/11/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-15.0%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,207 funds in the US Equity category with an average
ALTAR Score™ of 5.4% and a standard deviation
of 2.1%. CNCR's ALTAR Score™ is approximately -9.7 standard
deviations above the category average. This places CNCR in the 1st percentile
among funds in the category.
Sell-Side Consensus
$
PRICE TARGET
-100.0%
UPSIDE